Abstract
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News-New research on Drugs and Therapies-Personalized Medicine is the subject of a report. According to news originating from Santiago de Compostela, Spain, by NewsRx correspondents, research stated, " Chronic myelomonocytic leukaemia (CMML) is a rare haematological disorder charac terized by monocytosis and dysplastic changes in myeloid cell lineages. Accurate risk stratification is essential for guiding treatment decisions and assessing prognosis." Our news journalists obtained a quote from the research from the University Hosp ital of Santiago de Compostela, "This study aimed to validate the Artificial Int elligence Prognostic Scoring System for Myelodysplastic Syndromes (AIPSS-MDS) in CMML and to assess its performance compared with traditional scores using data from a Spanish registry (n = 1343) and a Taiwanese hospital (n = 75). In the Spa nish cohort, the AIPSS-MDS accurately predicted overall survival (OS) and leukae mia-free survival (LFS), outperforming the Revised-IPSS score. Similarly, in the Taiwanese cohort, the AIPSS-MDS demonstrated accurate predictions for OS and LF S, showing superiority over the IPSS score and performing better than the CPSS a nd molecular CPSS scores in differentiating patient outcomes. The consistent per formance of the AIPSS-MDS across both cohorts highlights its generalizability. I ts adoption as a valuable tool for personalized treatment decision-making in CMM L enables clinicians to identify high-risk patients who may benefit from differe nt therapeutic interventions."
NETL
NSTL